Bisphosphonates for osteoporosis prevention and treatment

Clinical Reviews in Bone and Mineral Metabolism

Volumn 3, Issue 1, 2005, Pages 3-18

  Jarvis, Courtney I ^a   Morin, Anna K ^a   Lynch, Ann M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Alendronate; Bisphosphonates; Clodronate; Etidronate; Ibandronate; Osteoporosis; Pamidronate; Risedronate; Tiludronate; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; GESTAGEN; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; PROTON PUMP INHIBITOR; PYROPHOSPHATE; RALOXIFENE; RISEDRONIC ACID; STEROID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ANOREXIA; AUDITORY HALLUCINATION; BACKACHE; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; CLINICAL TRIAL; CONJUNCTIVITIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ESOPHAGEAL IRRITATION; EYE PAIN; FRACTURE; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DYSFUNCTION; META ANALYSIS; NAUSEA; OLFACTORY HALLUCINATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT INFORMATION; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SENILE OSTEOPOROSIS; SYSTEMATIC REVIEW; TREATMENT INDICATION; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE; VISUAL IMPAIRMENT; VOMITING;

EID: 26244433459     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/bmm:3:1:003     Document Type: Review

References (94)

1. Fleisch H. 1998 Bisphosphonates: mechanisms of action. Endo Rev 19:80-100.
2. Rogers MJ, Russell RGG. 1999 Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106.
3. Vasikaran SD. 2001 Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38:608-623.
4. Lin JH. 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85.
5. Van Beek ER, Lowik CW, Papapoulos SE. 2002 Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30:64-70.
6. Cranney A, Guyatt G, Krolicki N, et al. 2001 A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Research Advisory Group. Osteoporos Int 12:140-151.
7. Storm T, Kollerup G, Thamsborg G, et al. 1996 Five years of clinical experience with intermittent cyclic etidronate for postmenopausal osteoporosis. J Rheumatol 23:1560-1564.
8. van Staa TP, Abenhaim L, Cooper C. 1998 Use of cyclic etidronate and prevention of nonvertebral fractures. Brit J Rheumatol 37:87-94.
9. Wimalawansa SJ. 1998 A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104:219-226.
10. Miller PD, Watts NB, Licata AA, et al. 1997 Cyclic etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103:468-476.
11. Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis of osteoporosis in Canada. Can Med Assoc J 2002;167(10 Suppl):S1-S34.
12. Filipponi P, Cristallini S, Policani G, et al. 2000 Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone 26:269-274.
13. McCloskey E, Selby P, de Takats D, et al. 2001 Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28:310-315.
14. Del Puente A, Scognamiglio A, Itto E, et al. 2000 Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol 27;1980-1983.
15. Reginster JY, Lecart MP, Deroisy R, et al. 1989 Prevention of postmenopausal bone loss by tiludronate. Lancet 2:1469-1471.
16. Cranney A, Wells G, Willan A, et al. 2002 Meta-analysis of alendronate for the treatment of menopausal women. Endocr Rev 23:508-516.
17. Bone HG, Hosking D, Devogelear JP, et al. 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199.
18. Recker R, Ensrud K, Diem S, et al. 2004 Normal Bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Metab 19(Suppl 1):S45 (abstract).
19. Black D, Schwartz A, Ensrud K, et al. 2004 A 5 year randomized trial of the long-term efficacy and safety of alendronate: The FIT Long-term Extension (FLEX). J Bone Miner Metab 04;19(Suppl 1):S45 (abstract).
20. Heijckmann AC, Juttman JR, Wolffenbuttel BH. 2002 Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 60:315-319.
21. Watts NB. 2001 Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27:197-214.
22. Peretz A, Body JJ, Dumon JC, et al. 1996 Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 25:69-75.
23. Wilkinson JM, Stockley I, Peel NF, et al. 2001 Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. J Bone Miner Res 16:556-564.
24. Krieg MA, Seydoux C, Sandini L, et al. 2001 Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporosis Int 12:112-116.
25. Hawthorne CS, Shelby PL, Adams JE, et al. 2001 Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 56:314-316.
26. Vis M, Bultink L, Dijkmans B, Lems W. 2004 The effect of oral alendronate versus intravenous pamidronate on bone mineral density in patients with ostreoporosis. J Bone Miner Metab 19(Suppl 1):S311 (abstract).
27. Harris St, Watts NB, Ganant HK, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282:1344-1352.
28. Sorenson OH, Crawford GM, Mulder H, et al. 2003 Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120-126.
29. McClung M, Geusens P, Miller P, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340.
30. Cranney A, Tugweel P, Adachi J, et al. 2002 Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523.
31. Rosen C, Hochberg M, Bonnick S, et al. 2004 Alendronate produces greater gains in BMD than risedronate with similar tolerability. J Bone Miner Metab 19(Suppl 1):S94 (abstract).
32. Roche Laboratories, Inc. 2003 Product Information: Boniva® (ibandronate sodium) tablets product information. Nutley, NJ.
33. Tankó LB, McClung MR, Schimmer RC, et al. 2003 The efficacy of 48-week ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 32:421-426.
34. Tankó LB, Felsenberg D, Czerwinski E, et al. 2003 Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254:159-167.
35. Cooper C, Emkey RD, McDonald RH, et al. 2003 Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:4609-4615.
36. Delmas PD, Recker RR, Chestnut III CH, et al. 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risks: results from the BONE study. Osteoporos Int 15:792-798.
37. Chestnut III CH, Skag A, Christiansen C, et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249.
38. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. 2003 Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62:969-975.
39. Thiebaud D, Burckhardt P, Kriegbaum H, et al. 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307.
40. Miller PD, Drezner MK, Delmas PD, et al. 2004 Monthly oral ibandronate is at least as effective as oral daily ibandronate in postmenopausal osteoporosis: 1-Year results from MOBILE. J Bone Miner Metab 19(Suppl 1):S94 (abstract).
41. Lewiecki E, Miller PD, Lorene R, et al. 2004 Monthly oral ibandronate is well tolerated in women with postmenopausal osteoporosis: 1-year results from MOBILE. J Bone Miner Metab 19(Suppl 1):S446 (abstract).
42. Emkey R, Felsenberg D, Stepan IJ, et al. 2004 Once monthly dosing increases the proportion of patients who respond to oral inbandronate: 1-year results from MOBILE. J Bone Miner Metab 19(Suppl 1):S447 (abstract).
43. Li EC, Davis LE. 2003 Zoledronic acid: A new parenteral bisphosphonate. Clin Ther 25:2669-2708.
44. Reid IR, Brown JP, Burckhardt P. 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661.
45. Saag KG, Emkey R, Schnitzer TJ, et al. 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Eng J Med 339:292-299.
46. Orwoll E, Ettinger M, Weiss S, et al. 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610.
47. Ringe JD, Faber H, Dorst A. 2001 Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Met 86:5252-5255.
48. Olszynski WP, Davison KS, Adachi JD, et al. 2004 Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26:15-28.
49. Finklestein JS, Hayes A, Hunzelman JL, et al. 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 394:1216-1226.
50. Lindsay R, Cosman F, Lobo RA, et al. 1999Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076-3081.
51. Bone HG, Greenspan SL, McKeever C, et al. 2000 Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 85:720-726.
52. Harris ST, Eriksen EF, Davidson M, et al. 2001 Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890-1897.
53. D'Amelio P, Muratore M, Tinelli F, et al. 2003 Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women. Int J Tissue React 25:73-78.
54. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. 2002 Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985-992.
55. Black DM, Greenspan SL, Ensrud KE, et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
56. Rittmaster RS, Bolognese M, Ettinger MP. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85 (6): 2129-2134.
57. Ettinger B, San Martin J, Crans G, Pavo I. 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751
58. Adler RA, Hochberg MC. 2003 Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veterans' affairs. Arch Intern Med 63:2619-2624.
59. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- induced Osteoporosis. 2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496-1503.
60. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. 2000 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 160:2917-2925.
61. Adachi JD, Saag KG, Delmas PD, et al. 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticosteroids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202-211.
62. Adachi JD, Bensen WG, Brown J, et al. 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Eng J Med 337:382-387.
63. Roux C, Oriente P, Laan R, et al. 1998 Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:1128-1133.
64. Pitt P, Li F, Todd P, et al. 1998 A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 53:351-6.
65. Saag KG, Emkey R, Schnitzer TJ, et al. 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Eng J Med 339:292-299.
66. Reid DM, Hughes RA, Laan RF, et al. 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006-1123.
67. Cohen S, Levy RM, Keller M, et al. 1999 Risedronate therapy prevents corticosteroid-induced osteoporosis bone loss. Arthritis Rheum 42:2309-2318.
68. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. 2001 Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, and infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104-112.
69. Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R. 2003 Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 33:575-581.
70. Ringe JD, Dorst H, Faber K, Preuss I, Preuss J. 2003 Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 42:743-749.
71. Bauer DC, Black D, Enstrud K, et al. 2000 Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517-525.
72. Olszynski WP, Davison KS, Adachi JD, et al. 2004 Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26:15-28.
73. Anonymous Bisphosphonates. Drug Interaction Facts, vol. 2004. eFacts; www.efactsonline.com. Accessed August 31, 2004.
74. Cryer R, Bauer DC. 2002 Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77:1031-43.
75. Lowe CE, Depew WT, Vanner SJ, et al. 2000 Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 95:634-640.
76. Aki S, Eskiyurt N, Akarirmak U, et al. 2003 Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 44:961-967.
77. Miller PD, Woodson G, Licata AA, et al. 2000 Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22:1433-1442.
78. Greenspan S, Field-Munves E, Tonino R, et al. 2002 Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044-1052.
79. Lanza F, Sahba B, Schwartz H, et al. 2002 The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo controlled endoscopy study. Am J Gastroenterol 97:58-64.
80. Brown JP, Kendler DL, McClung MR, et al. 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111.
81. Body JJ. 2001 Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28(4 Suppl 11):49-53.
82. Coleman CI, Perkerson KA, Lewis A. 2004 Alendronate-induced auditory hallucinations and visual disturbances. Pharmacotherapy 24:799-802.
83. Fraunfelder FW, Fraunfelder FT. 2003 Bisphosphonates and ocular inflammation. N Engl J Med 348:1187-1188.
84. Ryan PJ. 2000 Timing of cyclical etidronate. Clin Exp Rheumatol 18:609-612.
85. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. 2004 Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? J Bone Miner Metab 19(Suppl 1):S448 (abstract).
86. Recker R, Gallagher R, Amonkar M, et al. 2004 Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Metab 19(Suppl 1):S172 (abstract).
87. Caerano PA, Leslie WD, Mewrge CJ. 2004 The influence of bone mineral density testing on the initiation of an osteoporosis-related pharmacotherapy: a population-based analysis. J Bone Miner Metab 19(Suppl 1):S319 (abstract).
88. Merck and Co., Inc. 2004 Fosamax® (alendronate sodium) tablets and oral solution product information. Whitehouse Station, NJ.
89. Aventis Pharmaceuticals, Inc. 2003 Actonel® (risedronate sodium) tablets product information. Kansas City, MO.
90. Sanofi-Synthelabo, Inc. 2003 Skelid® (tiludronate disodium) tablets product information. New York, NY.
91. Proctor & Gamble Pharmaceuticals. 2003 Didronel® (etidronate sodium) tablets product information. Cincinnati, OH.
92. Novartis Pharmaceuticals. 2003 Aredia® (pamidronate disodium) for intravenous infusion product information. East Hanover, NJ.
93. Novartis Pharmaceuticals. 2004 Zometa® (zoledronic acid) concentrate for intravenous infusion product information. East Hanover, NJ.
94. Anonymous clodronate. Thompson MICROMEDEX®, vol. 2004; www.thomsonhc.com. Accessed August 31, 2004.